# Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis

> **NCT01194219** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 844 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Apremilast
- **DRUG:** Placebo
- **DRUG:** Topical treatments or phototherapy

## Key facts

- **NCT ID:** NCT01194219
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-09
- **Primary completion:** 2012-02-23
- **Final completion:** 2016-11-22
- **Target enrollment:** 844 (ACTUAL)
- **Last updated:** 2022-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01194219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01194219, "Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01194219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*